Global Digital Biomarkers Market is projected to witness a healthy growth rate of 35% from 2021 to 2026

Digital biomarkers are indexes that use data from digital platforms such as smartphones and wearable devices to objectively visualize the presence or absence of a disease, as well as changes caused by treatment. Digital biomarkers use advanced analytics and artificial intelligence (AI) algorithms to examine the data which would be impossible for humans to do alone.

High Investments and Fundings to develop Novel Technologies to fuel the Market Demands

It is predicted that digital biomarker is likely to be a vital tool for future diagnostic and treatment protocols for specific indications such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), cancer, among others. High growth of the digital biomarkers market has led to a number of investments and funding activities to accelerate research on digital biomarkers. Some of these are listed below:

  • In May 2022, Imagene AI, an Israel based digital biomarker company, secured US$ 21.5 million funding that includes US$ 3 million in seed funding led by Blumberg Capital and Series A round of US$ 18.5 million led by technology-driven cancer medicine investors, to focus on precision medicine in cancer care.
  • In February 2022, Koneksa, a company engaged in designing and validating digital biomarkers raised US$ 45 million Series C Financing led by AyurMaya, joined by Takeda Ventures and Velosity Capital, and existing investors such as McKesson Ventures, Merck Global Health Innovation Fund, Novartis, and others, to accelerate the expansion of digital biomarker platform.
  • In August 2021, the Alzheimer’s Drug Discovery Foundation (ADDF), US, awarded a funding up to US$ 2 million to the Early Detection of Neurodegenerative diseases (EDoN) initiative for a joint research programme led by Alzheimer's Research UK, with the goal of developing a digital biomarker to identify Alzheimer's disease at its earliest stage.

Big pharmaceutical companies and government bodies extend focus on digital biomarkers to boost adoption of digital biomarkers market

Digital biomarkers are much more than fitness trackers and smartwatches. The digital biomarkers market has witnessed a number of big pharma companies partnering with innovative digital health start-ups to enhance the adoption of this technology and co-develop advanced solutions. With the huge burden caused by Covid-19 pandemic, government bodies have also shown interest for the development of digital biomarker based therapeutic solution. Some of the recent developments in this space are listed below:

  • In March 2022, AstraZeneca partnered with Huma Therapeutics, a UK-based medical technology company, to develop Software as a Medical Device (SaMD) companion apps for several therapeutic conditions by combining predictive algorithms, digital biomarkers, and real-world data.
  • In January 2021, Biogen announced its partnership with Apple for the development of cognitive health digital biomarkers by assessing the potential of iPhone and Apple Watch for conditions such as mild cognitive impairment (MCI).
  • In September 2020, National Institute of Health (NIH) awarded a contract to physIQ, a company that bring life-saving therapies to market faster. This contract is aimed at developing an innovative AI-based COVID-19 digital biomarker solution.

Competitive Landscape Analysis: Global Digital Biomarkers Market

The global digital biomarkers market is marked by the presence of leading market players such as ActiGraph, LLC (US), AliveCor Inc. (US), Amgen Inc. (US), Biogen Inc. (US), AiCure (US), AstraZeneca (UK), and others.

Get Customized Report on Digital Biomarkers Market @ https://meditechinsights.com/digital-biomarkers-market/

Comments

Post a Comment

Popular posts from this blog

Global Healthcare Companion Robots Market valued at about $3 billion (2020), is growing at a lucrative CAGR close to 20% through 2020-2025

Companion robots offer companionship and emotional support for the children, elderly, and disabled people. Over the years, the improvements in sensors, actuators, and AI have led to rise in interest in healthcare companion robots market. Rising aging population, the rising cost of elder care, and shortage of caregivers The population across the globe is aging and the number of caregivers in relation to the aging population is declining. In Japan, there will be an estimated shortage of 1 million caregivers by 2025. Moreover, the cost of elder care is also rising. Between 2019 and 2020, the cost of in-home care jumped by about 4.4%; assisted living costs surged by 6.2%; and nursing home costs increased by 3%. The use of robots instead could help reduce this cost. For instance, a monthly service contract for Stevie (a robot developed by Trinity College, Dublin) would likely run between 50-60% of the cost of hiring a human to do the same tasks, as per their claim. “The growing dispar...
Read more

Global Mycoplasma Testing Market is slated to see a lucrative growth rate of 11% by 2027

Mycoplasmas are the smallest known free-living microorganisms and are frequent contaminants of mammalian cell cultures. For the safety and purity of vaccines and other biological cell-derived products, it is crucial that the cell substrates and unprocessed bulk materials are free of adventitious agents, including mycoplasma.  In many cases, mycoplasmas vary from other forms of bacteria, making them difficult to culture and identify. Testing is done to detect mycoplasma like Mycoplasma hominis, Mycoplasma genitalium, Mycoplasma pneumoniae, and Ureaplasma urealyticum which can cause nongonococcal urethritis (NGU), prostate inflammation (prostatitis), vaginal discharge, and pelvic inflammatory disease (PID) in both men and women. Rising Concerns of Cell Culture Contamination to Trigger the Growth of the Global Mycoplasma Testing Market Mycoplasmas randomly contaminate the fluids used in the bioprocessing and cell culture. It is commonly known that primary cell cultures have a minimum...
Read more

Global Obesity Drugs Market valued at $2.3 billion in 2022, is expected to Witness a Healthy Growth of 25% by 2027

Obesity and overweight are defined as gain of additional fat thus leading to a number of diseases, which can be measured by using body mass index (BMI) as a baseline. A BMI of over 30 is generally considered as obese and a BMI of over 25 is considered as overweight. Obesity is a major risk factor to various diseases such as diabetes, heart diseases, and cancer; approximately over 650 million obese patients living across the world as as projected by World Health Organization (WHO). Rising Obese and Overweight Population to Trigger the Demand of Obesity Drugs Market Obesity is one of the topmost contributors to a number of medical diseases such as heart diseases, stroke, cancer and diabetes. World Obesity Atlas 2022 forecasted the growth of global obese population to be 16.1% in 2025, accounting for 892 million people which will further reach 1,025 million by 2030 with a healthy growth rate of 17.5% in 2030.  Some of the regional obesity burden estimated by World Obesity Atlas 202...
Read more